Shareholding disclosure

Goodman & Company, Investment Counsel Ltd

Declared position

10.8%

Threshold

Crossed upwards

Timeline

Published

03.02.2010

Transaction

25.01.2010

Voting rights breakdown

Voting rights acquired10.8%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAA2200043

Beneficial owner

Goodman & Company, Investment Counsel Ltd

Declared address

Goodman & Company, Investment Counsel Ltd, M5C 2V9 Toronto

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Goodman & Company, Investment Counsel Ltd

Newron Pharmaceuticals S.p.A.03.02.2010TAA2200043

Disclosure summary

Goodman & Company, Investment Counsel Ltd disclosed a holding in Newron Pharmaceuticals S.p.A. on the acquisition side, published by SIX Exchange Regulation on 03.02.2010, at 10.8% of voting rights. Notice category: Single shareholder.

Disclosed position

10.8%

Voting rights acquired

Voting rights acquired10.8%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Goodman & Company, Investment Counsel Ltd disclosed a holding in Newron Pharmaceuticals S.p.A., published on 03.02.2010.

Publication date03.02.2010

Transaction date25.01.2010

Issuing companyNewron Pharmaceuticals S.p.A.

Beneficial ownerGoodman & Company, Investment Counsel Ltd

Declared addressGoodman & Company, Investment Counsel Ltd, M5C 2V9 Toronto

CategorySingle shareholder

Voting rights acquired10.8%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAA2200043

Source: SIX Exchange Regulation · Publication date: 03.02.2010

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open